X
30.64
-2.91 (-8.67%)
| Previous Close | 33.55 |
| Open | 33.57 |
| Volume | 1,095,883 |
| Avg. Volume (3M) | 449,290 |
| Market Cap | 2,345,271,296 |
| Price / Book | 3.61 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.01 |
| Total Debt/Equity (MRQ) | 1.19% |
| Current Ratio (MRQ) | 17.85 |
| Operating Cash Flow (TTM) | -181.39 M |
| Levered Free Cash Flow (TTM) | -117.59 M |
| Return on Assets (TTM) | -19.80% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Mixed |
| Biotechnology (Global) | Bearish | Mixed | |
| Stock | Xenon Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.88 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 103.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 67.00 (Deutsche Bank, 118.67%) | Buy |
| Median | 60.00 (95.82%) | |
| Low | 53.00 (HC Wainwright & Co., 72.98%) | Buy |
| Average | 60.00 (95.82%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 38.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Feb 2025 | 53.00 (72.98%) | Buy | 38.37 |
| Deutsche Bank | 11 Feb 2025 | 67.00 (118.67%) | Buy | 38.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | Xenon to Present at Stifel 2025 Virtual CNS Forum |
| 27 Feb 2025 | Announcement | Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update |
| 25 Feb 2025 | Announcement | Xenon to Present at the 45th Annual TD Cowen Healthcare Conference |
| 20 Feb 2025 | Announcement | Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 |
| 13 Jan 2025 | Announcement | Xenon Outlines Key Corporate Milestone Opportunities for 2025 |
| 07 Jan 2025 | Announcement | Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |